TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. announced the conversion of its Tranche A and Tranche B convertible bonds, valued at US$15 million and US$10 million respectively, into shares at a conversion price of HK$3.672 per share. This move is part of the company’s broader financial strategy, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (HK:2186) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company is listed on the Hong Kong Stock Exchange and is involved in the issuance of convertible bonds as part of its financial operations.
Average Trading Volume: 102,726,259
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.83B
Find detailed analytics on 2186 stock on TipRanks’ Stock Analysis page.